

Revance Therapeutics, Inc.
Form 4
February 11, 2014

FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
WOOTEN RONALD J

(Last) (First) (Middle)

C/O NOVAQUEST CAPITAL MANAGEMENT, L.L.C., 4208 SIX FORKS ROAD, SUITE 920

(Street)

RALEIGH, NC 27609

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol

Revance Therapeutics, Inc. [RVNC]

3. Date of Earliest Transaction (Month/Day/Year)

02/11/2014

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | | |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|---|---|---|
| | | | Code | V | Amount | (A) or (D) | Price | | |
| Common Stock | 02/11/2014 | | C | | 2,039,382 (1) | A | (2) 2,039,382 | I | by NovaQuest Pharma Opportunities Fund III, L.P. (3) |
| Common Stock | 02/11/2014 | | C | | 658,551 (4) | A | (4) 2,697,933 | I | by NovaQuest Pharma Opportunities Fund III, L.P. (3) |
| | 02/11/2014 | | X | | | A | (5) 3,096,650 | I | |

Edgar Filing: Revance Therapeutics, Inc. - Form 4

| | | |
|-----------------|-----------------------|---|
| Common Stock | 398,717 <u>(5)</u> | by NovaQuest Pharma Opportunities Fund III, L.P. <u>(3)</u> |
|-----------------|-----------------------|---|

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | Amount Number Shares | |
|---|--|---|---|--------------------------------------|--|--|---|----------------------------|---------------------|
| | | | | Code | V (A) (D) | Date Exercisable | Expiration Date | Title | |
| Series E-4 Convertible Preferred Stock | <u>(2)</u> | 02/11/2014 | | C | 1,539,343 | <u>(2)</u> | <u>(2)</u> | Common Stock | 1,539, |
| Series E-5 Convertible Preferred Stock | <u>(2)</u> | 02/11/2014 | | C | 500,039 | <u>(2)</u> | <u>(2)</u> | Common Stock | 500,0 |
| Convertible Promissory Notes | <u>(4)</u> | 02/11/2014 | | C | 658,551 <u>(4)</u> | <u>(4)</u> | <u>(4)</u> | Common Stock | 658,5 <u>(4)</u> |
| Warrant to Purchase Common Stock | <u>(6)</u> | 02/11/2014 | | X | 398,717 <u>(7)</u> | <u>(6)</u> | <u>(6)</u> | Common Stock | 398,7 <u>(7)</u> |

Reporting Owners

Reporting Owner Name / Address

Relationships

Reporting Owners

Director 10% Owner Officer Other

WOOTEN RONALD J
 C/O NOVAQUEST CAPITAL MANAGEMENT, L.L.C. X X
 4208 SIX FORKS ROAD, SUITE 920
 RALEIGH, NC 27609

Signatures

/s/ Gordon Ho, 02/11/2014
 Attorney-in-fact

 **Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
 ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Issued upon conversion of Series E-4 and E-5 Preferred Stock upon closing of the Issuer's initial public offering.
 (2) Each share of the Issuer's Series E-1, Series E-2, Series E-3, Series E-4 and Series E-5 Preferred Stock automatically converted into 1 share of the Issuer's Common Stock upon the closing of the Issuer's initial public offering and has no expiration date.

These securities are held by NovaQuest Pharma Opportunities Fund III, L.P. ("NovaQuest"). NQ HCIF General Partner, L.P., the general partner of NovaQuest ("NovaQuest GP"), has the power to vote and dispose of securities directly owned by NovaQuest, and NQ HCIF GP, Ltd., the general partner of NovaQuest GP ("NovaQuest GP Ltd."), has the power to direct the NovaQuest GP as to such voting and disposition. NovaQuest GP Ltd.'s investment committee, on which the Reporting Person, Ronald Wooten, serves, makes voting and investment decisions regarding securities held by NovaQuest. Mr. Wooten also serves on the board of directors of NovaQuest GP Ltd. Accordingly, Mr. Wooten may be deemed to have shared voting and dispositive power over the securities held by NovaQuest. Mr. Wooten disclaims beneficial ownership of the securities held by NovaQuest except to the extent of his pecuniary interest therein.

- (3) Convertible Promissory Notes in the aggregate principal amount of \$9,500,000.00 were issued between October 8, 2013 and January 16, 2014 by the Issuer pursuant to a Note and Warrant Purchase Agreement dated October 8, 2013, as amended. The principal amount of \$9,500,000.00 plus interest accrued through October 7, 2014, at the rate of 12% per annum converted automatically upon the closing of the Issuer's initial public offering into shares of Common Stock at a conversion price that equals to 100% of the per share price of the Common Stock sold in the Issuer's initial public offering.
 (4) Issued upon closing of the Issuer's initial public offering pursuant to automatic net exercise of warrants to purchase common stock at an exercise price of \$0.15 per share.
 (5) Automatically net exercised into shares of the Issuer's Common Stock at an exercise price of \$0.15 per share.
 (6) Includes certain warrants to purchase capital stock of the Issuer issued between October 8, 2013 and January 16, 2014 by the Issuer pursuant to a Note and Warrant Purchase Agreement dated October 8, 2013, as amended. The warrant shares were automatically net exercised into Common Stock of the Issuer upon the closing of the Issuer's initial public offering at a per share exercise price of \$0.15 per share on a post-split basis.
 (7)

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.